CL2018000385A1 - Compuestos di-nucleotido ciclico como agonistas agudos. - Google Patents

Compuestos di-nucleotido ciclico como agonistas agudos.

Info

Publication number
CL2018000385A1
CL2018000385A1 CL2018000385A CL2018000385A CL2018000385A1 CL 2018000385 A1 CL2018000385 A1 CL 2018000385A1 CL 2018000385 A CL2018000385 A CL 2018000385A CL 2018000385 A CL2018000385 A CL 2018000385A CL 2018000385 A1 CL2018000385 A1 CL 2018000385A1
Authority
CL
Chile
Prior art keywords
agonists
acute
cyclic compounds
nucleotide
nucleotide cyclic
Prior art date
Application number
CL2018000385A
Other languages
English (en)
Spanish (es)
Inventor
Michael D Altman
Brian Andresen
Wonsuk Chang
Matthew Lloyd Childers
Jared N Cumming
Andrew Marc Haidle
Timothy J Henderson
James P Jewell
Rui Liang
Jongwon Lim
Hong Liu
Min Lu
Alan P Northrup
Ryan D Otte
Tony Siu
Benjamin Wesley Trotter
Quang T Truong
Shawn P Walsh
Kake Zhao
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2018000385A1 publication Critical patent/CL2018000385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2018000385A 2015-08-13 2018-02-12 Compuestos di-nucleotido ciclico como agonistas agudos. CL2018000385A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204677P 2015-08-13 2015-08-13
US201562268723P 2015-12-17 2015-12-17
US201662356125P 2016-06-29 2016-06-29

Publications (1)

Publication Number Publication Date
CL2018000385A1 true CL2018000385A1 (es) 2018-08-17

Family

ID=56741193

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000385A CL2018000385A1 (es) 2015-08-13 2018-02-12 Compuestos di-nucleotido ciclico como agonistas agudos.

Country Status (29)

Country Link
US (4) US10106574B2 (und)
EP (2) EP3344644B1 (und)
JP (1) JP6596146B2 (und)
KR (2) KR102222186B1 (und)
CN (1) CN108137641B (und)
AU (1) AU2016304899B2 (und)
BR (1) BR112018002757A8 (und)
CA (1) CA2995365C (und)
CL (1) CL2018000385A1 (und)
CO (1) CO2018001425A2 (und)
CR (1) CR20180101A (und)
DO (1) DOP2018000046A (und)
EA (1) EA034786B1 (und)
GE (1) GEP20207182B (und)
HK (1) HK1249109A1 (und)
IL (1) IL257142B (und)
JO (1) JOP20200224A1 (und)
MA (1) MA42608A (und)
MX (1) MX2018001814A (und)
NI (1) NI201800025A (und)
PE (1) PE20180688A1 (und)
PH (1) PH12018500299A1 (und)
SG (1) SG10202010609QA (und)
SV (1) SV2018005632A (und)
TN (1) TN2018000023A1 (und)
TW (1) TWI696629B (und)
UA (1) UA123701C2 (und)
WO (2) WO2017027646A1 (und)
ZA (1) ZA201800442B (und)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008381B (zh) 2012-12-13 2018-08-07 艾杜罗生物科技公司 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
SG11201508273RA (en) 2013-05-18 2015-12-30 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
PE20170198A1 (es) 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
MA42146A (fr) 2015-03-10 2021-04-21 Aduro Biotech Inc Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
PE20180688A1 (es) 2015-08-13 2018-04-23 Merck Sharp & Dohme Compuestos di-nucleotidos ciclicos como agonistas de sting
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EA036421B1 (ru) 2016-01-11 2020-11-09 Иннэйт Тьюмор Иммьюнити, Инк. Соединения и композиции для лечения состояний, ассоциированных с активностью sting
LT3429596T (lt) 2016-03-18 2022-12-12 Immune Sensor, Llc Cikliniai dinukleotidų junginiai ir panaudojimo būdai
PE20181919A1 (es) 2016-04-07 2018-12-11 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN109843302B (zh) 2016-07-06 2022-11-29 F-星治疗公司 用于治疗疾病的化合物、组合物和方法
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3033542A1 (en) 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) * 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
PL3523287T3 (pl) 2016-10-04 2021-12-20 Merck Sharp & Dohme Corp. Związki benzo[b]tiofenu jako agoniści sting
EP3523314A1 (de) 2016-10-07 2019-08-14 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
EP3526323B1 (en) 2016-10-14 2023-03-29 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
RU2019122602A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
ES2891326T3 (es) * 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
AU2018212788A1 (en) * 2017-01-27 2019-07-25 Janssen Biotech, Inc. Cyclic dinucleotides as STING agonists
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018156625A1 (en) * 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
KR102808275B1 (ko) 2017-04-14 2025-05-20 탈락 테라퓨틱스, 인크. 면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
WO2018198084A1 (en) * 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018208667A1 (en) * 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2018232217A1 (en) * 2017-06-16 2018-12-20 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment of cancer
EP3431484A1 (en) * 2017-07-21 2019-01-23 Ludwig-Maximilians-Universität München A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
AU2018323053A1 (en) 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019046496A1 (en) * 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
US10947263B2 (en) * 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) * 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CA3078309A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Methods for administering sting agonists
EP3694867A1 (en) 2017-10-10 2020-08-19 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102747388B1 (ko) * 2017-10-16 2024-12-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
AU2018364708A1 (en) 2017-11-10 2020-05-21 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
EA038805B1 (ru) * 2017-11-21 2021-10-21 Такеда Фармасьютикал Компани Лимитед Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
JP7317014B2 (ja) * 2017-12-15 2023-07-28 ヤンセン バイオテツク，インコーポレーテツド Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3505527A1 (en) * 2017-12-29 2019-07-03 Invivogen Cyclic dinucleotides for cytokine induction
US11813326B2 (en) * 2018-01-04 2023-11-14 Academia Sinica Cell-associating immunologic adjuvants for treatment enhancement
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
IL276844B2 (en) * 2018-02-21 2025-01-01 Scripps Research Inst Preparations containing substances of the type 1H-IMIDAZOL-1-YL)-3-PYRIDAZINECARBOXAMIDE) for the treatment of tumors
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
CN111801341B (zh) * 2018-03-08 2023-10-24 百时美施贵宝公司 作为抗癌剂的环二核苷酸
JP7337086B2 (ja) 2018-03-23 2023-09-01 武田薬品工業株式会社 スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法
EP3768310A1 (en) 2018-03-23 2021-01-27 Codiak BioSciences, Inc. Extracellular vesicles comprising sting-agonist
US20210024567A1 (en) * 2018-03-27 2021-01-28 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
WO2019185477A1 (en) 2018-03-27 2019-10-03 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
CN111971277B (zh) 2018-04-03 2023-06-06 默沙东有限责任公司 作为sting激动剂的苯并噻吩及相关化合物
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN110407879A (zh) * 2018-04-28 2019-11-05 杭州星鳌生物科技有限公司 Txs-wx类化合物的化学组成、制备方法及其在抗肿瘤中的应用
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CA3101368A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
CN108892700B (zh) * 2018-05-27 2020-07-07 杭州星鳌生物科技有限公司 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用
AU2019277679B2 (en) * 2018-06-01 2024-11-28 Eisai R&D Management Co., Ltd. Methods for the treatment of bladder cancer
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3820477A4 (en) * 2018-07-10 2022-07-13 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
AU2019322722A1 (en) 2018-08-16 2020-10-15 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
SMT202500141T1 (it) 2018-09-06 2025-05-12 Daiichi Sankyo Co Ltd Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici
EP3849615A1 (en) 2018-09-12 2021-07-21 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
MA53659A (fr) * 2018-09-21 2022-02-23 Shanghai De Novo Pharmatech Co Ltd Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
AU2019371206A1 (en) 2018-10-29 2021-05-27 Venenum Biodesign, LLC Novel sting agonists
US20220008346A1 (en) 2018-10-30 2022-01-13 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
JP2022509929A (ja) 2018-10-31 2022-01-25 ノバルティス アーゲー Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US20220033435A1 (en) * 2018-12-07 2022-02-03 Merck Sharp & Dohme Corp. Cyclic Di-Nucleotide Compounds as STING Agonists
EP3891164A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020135715A1 (zh) * 2018-12-29 2020-07-02 上海济煜医药科技有限公司 作为肿瘤免疫类的化合物及其应用
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
KR102620495B1 (ko) * 2019-01-10 2024-01-04 셴젠 잉 바이오파마수티칼 씨오., 엘티디. 시클릭 디뉴클레오티드 프로드러그 분자 및 이의 제조 방법과 응용
EP3917971A4 (en) * 2019-01-28 2022-11-30 University of Rhode Island Board of Trustees PHLIP®-MEDIATED INTRACELLULAR RELEASE OF IMMUNE-STIMULATING COMPOUNDS
US12384797B2 (en) 2019-02-13 2025-08-12 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
KR20210129671A (ko) 2019-02-15 2021-10-28 노파르티스 아게 3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3935066A1 (en) * 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
JP7350871B2 (ja) * 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3941528A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Extracellular vesicle conjugates and uses thereof
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
MX2021011241A (es) 2019-03-21 2022-01-19 Codiak Biosciences Inc Vesiculas extracelulares para administracion de vacunas.
EP3946370A4 (en) * 2019-03-29 2023-01-04 Merck Sharp & Dohme LLC STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN114127082A (zh) 2019-05-09 2022-03-01 阿里戈斯治疗公司 作为sting调节剂的经修饰的环状二核苷化合物
AU2020274899A1 (en) 2019-05-10 2022-01-06 Takeda Pharmaceutical Company Limited Antibody drug conjugates
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
JP7622031B2 (ja) 2019-07-05 2025-01-27 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
KR20220054794A (ko) 2019-07-19 2022-05-03 이뮨센서 테라퓨틱스, 인코포레이티드 항체-sting 작용제 접합체 및 면역요법에서의 이의 용도
TW202114710A (zh) * 2019-07-25 2021-04-16 英屬開曼群島商百濟神州有限公司 作為sting促效劑之環狀二核苷酸
CN114585623A (zh) 2019-08-02 2022-06-03 梅尔莎纳医疗公司 双[N-((5-氨基甲酰基)-1H-苯并[d]咪唑-2-基)吡唑-5-甲酰胺]衍生物和相关化合物作为STING（干扰素基因刺激物）激动剂用于治疗癌症
TWI883032B (zh) 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021062060A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
CA3152478A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Extracellular vesicle compositions
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US20230074558A1 (en) 2019-12-06 2023-03-09 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
KR20220143064A (ko) 2020-02-18 2022-10-24 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20220162130A (ko) 2020-02-28 2022-12-07 탈락 테라퓨틱스, 인크. 트랜스글루타미나제-매개된 접합
PH12022551961A1 (en) * 2020-03-06 2023-10-09 Daiichi Sankyo Co Ltd Antibody-drug conjugate including novel cyclic dinucleotide derivative
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3171623A1 (en) 2020-03-20 2021-09-23 Codiak Biosciences, Inc. Extracellular vesicles for therapy
WO2021202984A1 (en) 2020-04-02 2021-10-07 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. CANCER THERAPY METHODS
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
CA3178464A1 (en) 2020-05-15 2021-11-18 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with immune checkpoint inhibitors
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230174567A1 (en) * 2020-05-22 2023-06-08 Merck Sharp & Dohme Llc Synthesis of fluorinated nucleotides
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
EP4196131A1 (en) * 2020-08-14 2023-06-21 Merck Sharp & Dohme LLC Synthesis of fluorinated nucleotides
CN116113641A (zh) 2020-09-02 2023-05-12 第一三共株式会社 新型内－β－N－乙酰氨基葡萄糖苷酶
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
CA3192470A1 (en) 2020-09-23 2022-03-31 Tim SOOS Methods of producing extracellular vesicles
EP4217087A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
CN115160392A (zh) * 2020-10-20 2022-10-11 泰励生物科技（上海）有限公司 多功能环二核苷酸及其用途
KR20230107586A (ko) 2020-10-20 2023-07-17 타이리간드 바이오사이언스 (상하이) 리미티드 다기능성 사이클릭 디뉴클레오티드 및 이의 용도
KR102466750B1 (ko) * 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
PE20231947A1 (es) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco
CN116981479A (zh) 2020-12-17 2023-10-31 塔夫茨大学信托人 Fap激活的放射治疗诊断法以及与之相关的用途
WO2022204269A1 (en) * 2021-03-25 2022-09-29 The Regents Of The University Of Michigan Cyclic dinucleotide conjugates and related methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216577A1 (en) * 2021-04-09 2022-10-13 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
KR20230170745A (ko) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
US20240218009A1 (en) * 2021-04-21 2024-07-04 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
CA3226976A1 (en) 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
EP4137499A1 (en) 2021-08-17 2023-02-22 Ustav organicke chemie a biochemie AV CR, v.v.i. 7-substituted 7-deazaadenine-containing 2,3 -cyclic dinucleotides
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
CN114249786A (zh) * 2021-12-29 2022-03-29 上海彩迩文生化科技有限公司 含n,n-二酰基结构核苷中间体的制备和应用
CN118804983A (zh) 2022-03-02 2024-10-18 第一三共株式会社 含Fc分子的制造方法
WO2023176862A1 (ja) 2022-03-16 2023-09-21 第一三共株式会社 トランスフェリン受容体２の発現を抑制するｓｉＲＮＡ
CN118871585A (zh) 2022-03-16 2024-10-29 第一三共株式会社 具有RNAi活性的化学-修饰的寡核苷酸
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
US20240002414A1 (en) * 2022-06-29 2024-01-04 Si Group, Inc. Method of Making a Phosphite Ester
WO2024048490A1 (ja) 2022-08-29 2024-03-07 第一三共株式会社 変異Ｆｃ領域を含む抗体薬物コンジュゲート
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy
CN116675779B (zh) * 2023-05-26 2024-07-09 山东大学 一种靶向Src激酶的短肽及其在系统性真菌感染中的应用
CN120204418A (zh) * 2023-12-27 2025-06-27 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用
CN118027100B (zh) * 2024-03-07 2024-07-05 凯莱英生命科学技术(天津)有限公司 N2-iBu-鸟嘌呤-(S)-GNA亚磷酰胺单体的合成方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
EP1368458A2 (en) 2001-02-26 2003-12-10 Pharma Pacific Pty. Ltd. Interferon-alpha induced gene
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
WO2005005450A1 (ja) * 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. 環状ビスジヌクレオシドの合成方法
EP1740192B1 (en) 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US7326986B2 (en) 2006-01-06 2008-02-05 International Business Machines Corporation Trench memory
CA2855098C (en) 2007-06-18 2018-02-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN104740610A (zh) 2008-08-25 2015-07-01 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
WO2010047774A2 (en) 2008-10-20 2010-04-29 The Texas A & M University System Inhibitors of mycobacterium tuberculosis malate synthase, methods of marking and uses thereof
EP2376535B9 (en) 2008-12-09 2017-09-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
DE112009004064T5 (de) 2009-01-29 2012-06-14 Hewlett-Packard Development Company, L.P. Bereitstellen einer angabe einer veränderung an einernutzerschnittstellenvorrichtung über ein netzwerk zwischen computern
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
WO2014009941A1 (en) 2012-07-12 2014-01-16 Abdol Salam Gihleb Automatic motorcycle break-in apparatus
CN103840995B (zh) 2012-11-26 2017-10-24 华为技术有限公司 Ip报文处理方法、装置及网络系统
CN105008381B (zh) 2012-12-13 2018-08-07 艾杜罗生物科技公司 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
DK2934598T3 (en) 2012-12-19 2018-07-23 Univ Texas PHARMACEUTICAL TARGETING OF A CYCLIC MAMMAL DI DI NUCLEOTIDE SIGNAL ROAD
SG10201708821RA (en) * 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP6400082B2 (ja) * 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
SG11201508273RA (en) 2013-05-18 2015-12-30 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
WO2015077354A1 (en) 2013-11-19 2015-05-28 The University Of Chicago Use of sting agonist as cancer treatment
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
PE20170198A1 (es) * 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
US20170121315A1 (en) 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
PL3233882T3 (pl) 2014-12-16 2020-04-30 Kayla Therapeutics Fluorowane cykliczne dinukleotydy do indukcji cytokin
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
GB2534573A (en) 2015-01-27 2016-08-03 Bae Systems Plc Reactive materials
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
MA42146A (fr) 2015-03-10 2021-04-21 Aduro Biotech Inc Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
WO2017011622A1 (en) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors
JP2018522698A (ja) 2015-07-16 2018-08-16 ソナベックス インコーポレイテッドＳｏｎａｖｅｘ， Ｉｎｃ． 超音波エコー輝度を向上させるためのマイクロキャビティを含有するポリマー医療デバイス
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
PE20180688A1 (es) 2015-08-13 2018-04-23 Merck Sharp & Dohme Compuestos di-nucleotidos ciclicos como agonistas de sting
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3386536A4 (en) 2015-12-07 2019-07-31 Opi Vi- IP Holdco LLC COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
EA036421B1 (ru) 2016-01-11 2020-11-09 Иннэйт Тьюмор Иммьюнити, Инк. Соединения и композиции для лечения состояний, ассоциированных с активностью sting
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
LT3429596T (lt) 2016-03-18 2022-12-12 Immune Sensor, Llc Cikliniai dinukleotidų junginiai ir panaudojimo būdai
PE20181919A1 (es) 2016-04-07 2018-12-11 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
ES2993451T3 (en) 2016-06-13 2024-12-30 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF

Also Published As

Publication number Publication date
DOP2018000046A (es) 2018-04-15
US10106574B2 (en) 2018-10-23
IL257142A (en) 2018-03-29
UA123701C2 (uk) 2021-05-19
ZA201800442B (en) 2018-12-19
TN2018000023A1 (en) 2019-07-08
CA2995365C (en) 2021-10-12
CN108137641A (zh) 2018-06-08
US20170044206A1 (en) 2017-02-16
US20180237469A1 (en) 2018-08-23
IL257142B (en) 2021-04-29
EP3344644B1 (en) 2024-06-26
EA201890450A1 (ru) 2018-07-31
SV2018005632A (es) 2018-10-19
US10766919B2 (en) 2020-09-08
KR102222186B1 (ko) 2021-03-03
PE20180688A1 (es) 2018-04-23
WO2017027645A1 (en) 2017-02-16
GEAP201614726A (und) 2020-07-27
PH12018500299A1 (en) 2018-08-29
EP3334745B1 (en) 2024-05-15
WO2017027646A1 (en) 2017-02-16
JP2018522914A (ja) 2018-08-16
SG10202010609QA (en) 2020-11-27
KR20200116537A (ko) 2020-10-12
KR102271750B1 (ko) 2021-06-30
MA42608A (fr) 2018-06-20
CN108137641B (zh) 2022-04-01
NI201800025A (es) 2018-06-12
KR20180030926A (ko) 2018-03-26
BR112018002757A8 (pt) 2023-04-11
EP3344644A1 (en) 2018-07-11
MX2018001814A (es) 2018-05-07
US10738074B2 (en) 2020-08-11
BR112018002757A2 (und) 2018-10-02
CR20180101A (es) 2018-04-12
CA2995365A1 (en) 2017-02-16
US10759825B2 (en) 2020-09-01
US20180244712A1 (en) 2018-08-30
JP6596146B2 (ja) 2019-10-23
EP3334745A1 (en) 2018-06-20
CO2018001425A2 (es) 2018-05-10
TW201718619A (zh) 2017-06-01
AU2016304899B2 (en) 2018-11-08
US20180230178A1 (en) 2018-08-16
GEP20207182B (en) 2020-11-25
JOP20200224A1 (ar) 2022-10-30
EP3344644A4 (en) 2019-02-27
HK1249109A1 (zh) 2018-10-26
TWI696629B (zh) 2020-06-21
AU2016304899A1 (en) 2018-02-01
EA034786B1 (ru) 2020-03-20

Similar Documents

Publication Publication Date Title
CL2018000385A1 (es) Compuestos di-nucleotido ciclico como agonistas agudos.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
EA201792613A1 (ru) Модуляторы cot и способы их применения
CL2016000381A1 (es) Compuestos antivirales
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2016000918A1 (es) Compuestos derivados de pirimidin amidas con actividad inhibidora del factor de crecimiento fgfr (fgfr4 y fgf19); composición farmacéutica que los comprende y uso en el tratamiento del carcinoma hepatocelular.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
CL2015003370A1 (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
UA115773C2 (uk) Пірольні сполуки, спосіб їх одержання та фармацевтична композиція, що їх містить (варіанти)
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
EA201891479A1 (ru) Композиции и способы модулирования экспрессии hbv и ttr
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA202090620A1 (ru) Энантиомеры замещенных тиазолов в качестве противовирусных соединений
PH12018500379B1 (en) Biopharmaceutical compositions
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
EA201790057A1 (ru) Антитела-антагонисты к интерферону альфа и интерферону омега